We are thrilled to announce the launch of our new Anti-CA-125 antibody RX16 (Cat# 4C29), a recombinant product designed to enhance the accuracy and reliability of ovarian cancer diagnostics. With this innovative product, we aim to support healthcare professionals and researchers in their quest to improve early detection, monitoring, and treatment of ovarian cancer, ultimately leading to better patient outcomes.

Cancer antigen 125 (CA-125) is an antigenic tumor marker expressed by epithelial ovarian neoplasms as well as by cells lining various organs, including the endometrium, fallopian tubes, pleura, peritoneum, and pericardium. Recognizing its pivotal role, the National Institute for Health and Care Excellence (NICE) in 2011 advocated testing for the serum biomarker cancer antigen 125 (CA-125) in women with symptoms of possible ovarian cancer in primary care. Many other countries, including Ireland, Australia, Canada, and the US, also recommend CA-125 as a primary care test for ovarian cancer.

Our RX16 is developed using recombinant technology, ensuring exceptional lot-to-lot consistency. Understanding the critical importance of a robust and secure supply chain, we have implemented various measures to ensure the continuous and reliable availability of this new product, allowing us to meet increasing demand without compromising quality or consistency.